{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2"},{"groupId":"OG001","value":"82.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"306"},{"groupId":"OG001","value":"307"}],"units":"Participants"}],"description":"Fever and febrile neutropenia defined as Absolute Neutrophil Count (ANC) \\< 1000/mm3 with a single temperature of \\>38.3 degrees C (101 degrees F) or a sustained temperature of \\>= 38 degrees C (100.4 degrees F) for more than one hour.","groups":[{"description":"Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.\n\nlevofloxacin: Given PO or IV","id":"OG000","title":"Arm I (Levofloxacin)"},{"description":"Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.","id":"OG001","title":"Arm II (Standard of Care)"}],"paramType":"NUMBER","populationDescription":"All evaluable, and centrally reviewed AL and HSCT patients are reported. Ineligible patients and patients who withdrew of consent prior to treatment were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 60 days after enrollment or receiving levofloxacin","title":"Comparison of the Percentage of Patients Having Incidence of Fever and Febrile Neutropenia Between Arms","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}